Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152

@article{Ganneru2020EvaluationOS,
  title={Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152},
  author={Brunda Ganneru and Harsh Jogdand and Vijaya Kumar Dharam and Narasimha Reddy Molugu and Sai D. Prasad and Srinivas Vellimudu and Krishna M Ella and Rajaram Ravikrishnan and Amit Awasthi and Jomy Jose and Panduranga Rao and Deepak Kumar and Raches Ella and Priya Abraham and Pragya Dhruv Yadav and Gajanan N. Sapkal and Anita M. Shete and Gururaj Rao Desphande and Sreelekshmy Mohandas and Ananth Basu and Nivedita Gupta and Balram Bharagava and Krishna Mohan Vadrevu},
  journal={bioRxiv},
  year={2020}
}
We report the development and evaluation of safety and immunogenicity of a whole virion inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or a novel TLR7/8 agonist adsorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established vero cell platform to produce large-scale GMP grade highly purified inactivated antigen, BBV152. Product development and manufacturing were carried out in a BSL-3 facility. Immunogenicity was determined at two… 
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
TLDR
Interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152, 3{ micro} and 6{micro} with Algel-IMDG suggest that the safety profile of this vaccine is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.
Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt
TLDR
Immunogenicity of the developed vaccine indicated the high antigen-binding and neutralizing antibody titers, regardless of the dose concentration, with excellent safety profiles, which will support the future trials for evaluation an applicable SARS-CoV-2 vaccine candidate.
Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model
TLDR
The result showed that the purified RBD immunogen is stable up to 72 h, without any apparent loss in affinity or specificity of interaction with the ACE2 receptor, support the potential of RBD330-526 as a promising vaccine candidate against SARS-CoV-2.
Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration
TLDR
It is stressed that thermostabilizing technologies are available to enable cold chain-free vaccine storage and distribution, as well as potential needle-free vaccination.
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019
Animal models for SARS-CoV-2 and SARS-CoV-1 pathogenesis, transmission and therapeutic evaluation
TLDR
The present review summarizes the recent progress in developing animal models for these two pathogenic viruses and highlights the utility of these models in studying SARS-associated coronavirus diseases.
siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.
TLDR
The significance and potential of siRNA-based therapy to treat diverse viral infections in addition to the current coronavirus challenge is described and the patents approved for coronaviruses are reviewed, followed by innovation and prospects.
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models
TLDR
Of the three tested vaccine regimens, the middle dose of the vaccine showed the best protective immune parameters and this vaccine with heterologous prime-boost vaccination method can be a good candidate to control the viral infection and its spread by stimulating central and mucosal immunity.
Recent Update of COVID-19 Vaccines
TLDR
This review highlights the completed, and ongoing clinical trials of COVID-19 vaccines and efforts are being made globally to avert the pandemic.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
TLDR
A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year that corroborate with excellent seroprotection after the first dose of an earlier J ENVAC study and report appreciable interchangeability between both vaccines.
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains.
TLDR
JENVAC elicits long-lasting, broadly protective immunity and neutralized JEV genotypes I, II, III, and IV equally well, and immunogenicity criteria were higher than that for SA-14- 14-2 at 12, 18, and 24 months each.
Inactivated Viral Vaccines
TLDR
The principles of viral inactivation and the application of these principles to vaccine development are described and the manufacturing procedure and the accompanying assays, of which assays used for monitoring the inactivation process and preservation of neutralizing epitopes, are pivotal.
Two Doses of Parenterally Administered Split Influenza Virus Vaccine Elicited High Serum IgG Concentrations which Effectively Limited Viral Shedding upon Challenge in Mice
TLDR
The concentration of postvaccination serum IgG showed an inverse relationship with the level of viral shedding after viral challenge, and is an important factor in limiting viral replication in the upper respiratory tract upon challenge of an antigenically similar virus.
Rapid COVID-19 vaccine development
TLDR
The benefit of developing an effective vaccine is very high, and even greater if it can be deployed in time to prevent repeated or continuous epidemics.
...
...